Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same author

Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.

Circulation. Cardiovascular interventions·2026
Same author

Adult congenital cardiac interventional training, competencies, and organization. A Statement of the ESC ACHD Working Group, the EAPCI, the AEPC, and the PICS-Society.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Postoperative outcomes of Morel-Lavallee injuries and predictive factors for wound complications: A Pacific Coast Surgical Association multicenter study.

Surgery·2026
Same author

Prognostic Factors Associated With Mortality Among Patients With Necrotizing Soft-Tissue Infection: A Systematic Review and Meta-Analysis.

Critical care medicine·2026
Same author

Bile Acids, Mitochondria, and Myocardial Stiffness: A Shared Mechanism in Fontan Circulation and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Circulation. Heart failure·2026

Related Experiment Video

Updated: Jun 8, 2026

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.9K

Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled

Michael R Hainstock1, Gregory Fleming2, Dennis Kim3

  • 1University of Virginia, Charlottesville (M.R.H., D.S.L.).

Circulation. Cardiovascular Interventions
|March 26, 2026
PubMed
Summary

The SAPIEN 3 transcatheter heart valve (THV) shows durable safety and effectiveness for pulmonic valve replacement over 5 years. This study confirms its role in treating right ventricular outflow tract issues, with low reintervention and endocarditis rates.

Keywords:
endocarditishemodynamicspulmonary valve insufficiencypulmonary valve stenosisstents

More Related Videos

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
09:57

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement

Published on: January 20, 2022

3.3K
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

3.5K

Related Experiment Videos

Last Updated: Jun 8, 2026

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.9K
Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
09:57

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement

Published on: January 20, 2022

3.3K
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

3.5K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Medical Devices

Background:

  • The COMPASSION S3 trial investigated the SAPIEN 3 transcatheter heart valve (THV) for pulmonic valve replacement.
  • This addressed patients with dysfunctional right ventricular outflow tract (RVOT) conduits or previously implanted pulmonic valves.

Purpose of the Study:

  • To report 5-year clinical and hemodynamic outcomes of the SAPIEN 3 THV in the COMPASSION S3 trial.
  • To evaluate the safety and effectiveness of THV for pulmonic valve replacement.

Main Methods:

  • A single-arm, multicenter study (COMPASSION S3) enrolled patients with moderate-to-severe pulmonic regurgitation and high RVOT gradient.
  • The primary endpoint was THV dysfunction at 1 year, assessing reintervention, pulmonic regurgitation, and RVOT gradient.
  • Clinical and echocardiographic outcomes were tracked annually for 5 years.

Main Results:

  • At 5 years, THV dysfunction occurred in 12.0% of 69 patients, with low rates of reintervention (3 patients) and moderate pulmonic regurgitation (2 patients).
  • Device-related endocarditis occurred in 4.4% of patients; one death occurred at 560 days due to cardiogenic shock.
  • Post-procedure, mean gradients remained low, and >95% of patients had ≤mild pulmonic regurgitation at 5 years.

Conclusions:

  • Five-year follow-up of the COMPASSION S3 trial demonstrates durable RVOT relief with the SAPIEN 3 THV.
  • The device is a safe and versatile option for transcatheter pulmonic valve replacement, showing low reintervention and endocarditis rates.